TFF Pharmaceuticals Announces Results of Its 2020 Annual Meeting of Stockholders

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the results from its Annual Meeting of Stockholders, which took place virtually earlier today. All director nominees were elected to the Board of Directors and Marcum LLP was appointed as the Company’s independent registered public accounting firm for the 2020 fiscal year. A total of 18,076,265 common shares (representing approximately 83% of all issued and outstanding common shares of TFF) were represented at the meeting.

The detailed results of the Annual Meeting were as follows:

1. Election of Directors

All eight (8) nominees for the Board of Directors that were proposed by TFF’s management were elected as a Director of the Company. All the nominated directors were members of the Board of Directors of TFF prior to today’s Meeting. The votes were cast for each nominee as follows:

Nominee	Yes	Withheld
Aaron Fletcher, Ph.D.	11,253,545	28,609
Brian Windsor, Ph.D.	11,253,543	28,611
Stephen C. Rocamboli	11,253,546	28,608
Randy Thurman	11,253,545	28,609
Glenn Mattes	11,253,543	28,611
Robert S. Mills	11,094,669	187,485
Harlan Weisman, M.D.	11,183,280	98,874
Malcolm Fairbairn	11,253,504	28,650

2. Appointment of Auditor

Marcum LLP was appointed as the Company’s independent registered public accounting firm for the 2020 fiscal year. The votes were cast as follows:

Yes

No

Abstain